Diabetes Care, Vol 20, Issue 10 1539-1542, Copyright © 1997 by American Diabetes Association

ARTICLES

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes

MN Feinglos, CH Thacker, J English, MA Bethel and JD Lane
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. feing002@mc.duke.edu

OBJECTIVE: Insulin lispro is a rapid-acting analog of human insulin that can be used to target the postprandial rise in plasma glucose. We designed an open-label randomized crossover study of type 2 diabetic patients with secondary failure of sulfonylurea therapy to determine whether improvement of postprandial hyperglycemia would affect total daily glucose control. RESEARCH DESIGN AND METHODS: Twenty-five type 2 diabetic patients who were poorly controlled on a maximum dose of sulfonylureas were studied in a university hospital clinical research center. In one arm of the study, patients continued therapy with maximum-dose sulfonylureas. In the other arm, patients used a combination therapy with insulin lispro before meals and sulfonylureas. After 4 months, patients were crossed over to the opposite arm. Fasting plasma glucose (FPG) and 1- and 2-h postprandial glucose (after a standardized meal), HbA1c, total, HDL, and LDL cholesterol, and triglyceride levels were measured at the end of each arm of the study. RESULTS: Insulin lispro in combination with sulfonylurea therapy significantly reduced 2-h postprandial glucose concentrations compared with sulfonylureas alone, from 18.6 to 14.2 mmol/l (P < 0.0001), and incremental postprandial glucose area from 617.8 to 472.9 mmol.min.1-1 (P < 0.0007). FPG levels were decreased from 10.9 to 8.5 mmol/l (P < 0.0001), and HbA1c values were reduced form 9.0 to 7.1% (P < 0.0001). Total cholesterol was significantly decreased in the lispro arm from 5.44 to 5.10 mmol/l (P < 0.02). HDL cholesterol concentrations were increased in the lispro arm from 0.88 to 0.96 mmol/l (P < 0.01). The patients weighed significantly more after lispro therapy than after sulfonylureas alone, but the difference was small in absolute terms (sulfonylurea therapy alone, 90.6 kg; lispro therapy, 93.8 kg; P < 0.0001). Two episodes of hypoglycemia (glucose concentrations, < 2.8 mmol/l) were reported by the patients while using lispro. CONCLUSIONS: Previously, it has not been possible to address the effect of treatment of postprandial hyperglycemia specifically. We have now shown that the treatment of postprandial hyperglycemia with insulin lispro markedly improves overall glucose control and some lipid parameters in patients with type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W. S. Shim, S. K. Kim, H. J. Kim, E. S. Kang, C. W. Ahn, S. K. Lim, H. C. Lee, and B. S. Cha Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur. J. Endocrinol., October 1, 2006; 155(4): 615 - 622. [Abstract] [Full Text] [PDF]

				C. Robertson Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control. The Diabetes Educator, May 1, 2006; 32(3): 423 - 432. [Abstract] [Full Text] [PDF]

				L. Siminerio Challenges and strategies for moving patients to injectable medications. The Diabetes Educator, March 1, 2006; 32(2 Suppl): 82S - 90S. [Full Text] [PDF]

				M. Kirby Initiating insulin in patients with type 2 diabetes within primary care The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 122 - 125. [Abstract] [PDF]

				A. J. Garber Benefits of Combination Therapy of Insulin and Oral Hypoglycemic Agents Arch Intern Med, August 11, 2003; 163(15): 1781 - 1782. [Full Text] [PDF]

				C. Homko, A. Deluzio, C. Jimenez, J. W. Kolaczynski, and G. Boden Comparison of Insulin Aspart and Lispro: Pharmacokinetic and metabolic effects Diabetes Care, July 1, 2003; 26(7): 2027 - 2031. [Abstract] [Full Text] [PDF]

				J. Davidson Should Postprandial Glucose Be Measured and Treated to a Particular Target? Yes. Diabetes Care, June 1, 2003; 26(6): 1919 - 1921. [Full Text] [PDF]

				J. B. Meigs, D. M. Nathan, R. B. D'Agostino Sr, and P. W.F. Wilson Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk: The Framingham Offspring Study Diabetes Care, October 1, 2002; 25(10): 1845 - 1850. [Abstract] [Full Text] [PDF]

				C. G. Parkin and N. Brooks Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings? Clin. Diabetes, April 1, 2002; 20(2): 71 - 76. [Abstract] [Full Text] [PDF]